Vanguard Group Inc Vigil Neuroscience, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Vigil Neuroscience, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 904,731 shares of VIGL stock, worth $2.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

904,731

Previous 814,731 11.05%

Holding current value

$2.73 Million

Previous $3.26 Million 5.59%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$2.92 - $4.65 $262,800 - $418,500	90,000 Added 11.05%	904,731 $3.08 Million
Q2 2024 Aug 13, 2024	SELL	$2.51 - $4.66 $200,152 - $371,597	-79,742 Reduced 8.91%	814,731 $3.26 Million
Q1 2024 May 10, 2024	BUY	$2.68 - $3.63 $255,339 - $345,851	95,276 Added 11.92%	894,473 $3.05 Million
Q4 2023 Feb 14, 2024	BUY	$2.97 - $8.6 $15,536 - $44,986	5,231 Added 0.66%	799,197 $2.7 Million
Q3 2023 Nov 14, 2023	BUY	$4.8 - $9.92 $8,304 - $17,161	1,730 Added 0.22%	793,966 $4.28 Million
Q2 2023 Aug 14, 2023	BUY	$8.11 - $10.54 $515,982 - $670,586	63,623 Added 8.73%	792,236 $7.45 Million
Q1 2023 May 15, 2023	SELL	$8.77 - $12.7 $73,668 - $106,680	-8,400 Reduced 1.14%	728,613 $7.13 Million
Q4 2022 Feb 10, 2023	BUY	$8.74 - $15.99 $3.25 Million - $5.94 Million	371,587 Added 101.69%	737,013 $9.21 Million
Q3 2022 Nov 14, 2022	BUY	$2.37 - $9.61 $26,586 - $107,804	11,218 Added 3.17%	365,426 $3.33 Million
Q2 2022 Aug 12, 2022	SELL	$2.23 - $7.81 $69,107 - $242,031	-30,990 Reduced 8.05%	354,208 $914,000
Q1 2022 May 13, 2022	BUY	$7.03 - $17.29 $2.71 Million - $6.66 Million	385,198 New	385,198 $2.71 Million

Others Institutions Holding VIGL

# of Institutions

Shares Held

27.9M

Call Options Held

Put Options Held

View Full List

About Vigil Neuroscience, Inc.

Ticker VIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,268,600
Market Cap $85.4M
Description
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...

More about VIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Vigil Neuroscience, Inc. Transaction History